Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial
| Autor: | Branchoux, S., Sofeu, C.L., Gaudin, A.-F., Kurt, M., Moshyk, A., Italiano, A., Bellera, C., Rondeau, V. |
|---|---|
| Zdroj: | In ESMO Open February 2022 7(1) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|